Skip to content
Open access

Amyloid-Tau PET Fusion Reveals Covarying Network Territories Linked to Disease Stage, Cognition, and APOE4 in Alzheimer’s Disease

Aug 2026 · bioRxiv · 0 citations
Biology

TL;DR

High-order joint independent component analysis was used to identify fine-grained, data-driven patterns of Amyloid-Tau covariance across individuals, and overlapping abnormality was also associated with cognition across the greatest number of components and showed the strongest overall association with ADAS13.

Abstract

Background Amyloid-beta (Aβ) and Tau are defining pathologies of Alzheimer’s disease, but their relationship varies substantially across the brain. Amyloid deposition is spatially widespread, whereas Tau shows greater regional heterogeneity and closer relationships with disease severity. Consequently, understanding the disease requires more than measuring the two pathologies independently or summarizing them within predefined regions. A major unresolved question is how Amyloid and Tau covary across the whole brain, where their spatial patterns converge or diverge, and whether their local combination carries distinct information about disease stage and cognition. Methods We analyzed paired florbetapir Amyloid PET and flortaucipir Tau PET from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), comprising 378 paired imaging sessions from 320 participants spanning cognitively normal (CN), mild cognitive impairment (MCI), and Alzheimer’s Dementia (AD). High-order joint independent component analysis was used to identify fine-grained, data-driven patterns of Amyloid-Tau covariance across individuals. The resulting Amyloid and Tau maps were characterized by their spatial similarity and correspondence with rsfMRI-derived intrinsic functional networks. We then used the same data-driven spatial regions to quantify, for each participant, the relative extent of Amyloid abnormality alone, Tau abnormality alone, and spatially overlapping Amyloid-Tau abnormality. Results Ninety-six non-artifactual Amyloid-Tau components were identified, of which 73 showed appreciable spatial correspondence between their paired Amyloid and Tau maps, while 17 were Tau-localized and 6 Amyloid-localized. Amyloid component maps more frequently corresponded with rsfMRI-derived intrinsic network organization than Tau maps. Expression of the joint components differed across diagnosis groups, demonstrating spatially heterogeneous disease-stage patterns. Within the same data-driven regions, isolated Amyloid, isolated Tau, and overlapping Amyloid-Tau abnormality showed markedly different disease-stage profiles: Amyloid-only abnormality was more prominent in the earlier CN-to-MCI contrast, Tau-only abnormality in contrasts involving AD, whereas spatially overlapping Amyloid-Tau abnormality showed the broadest differences across disease stages and the largest mean CN-to-AD expansion. Overlapping abnormality was also associated with cognition across the greatest number of components and showed the strongest overall association with ADAS13. APOE4-related diagnosis-stage differences were considerably more widespread for pathology measures containing Amyloid than for Tau-only abnormality.

Read PDF

Similar papers

Review Open access Oct 2026

Amyloid-β plaque diversity across brain regions in Alzheimer’s disease and its relation to major clinicopathological traits

Amyloid beta (Aβ) deposition and tau accumulation are neuropathological hallmarks of Alzheimer’s disease (AD). While Aβ deposits present with a wide morphological variety, a comprehensive, cross-regional overview of Aβ plaque composition in AD and associations with clinicopathological traits are missing. In this study,...

Antonia Neubauer, Paul L. C. Feyen, S. Pekrun et al. · 0 citations
Open access Oct 2026

Greater amyloid burden in cognitive networks in preclinical Alzheimer's disease.

BackgroundIn preclinical Alzheimer's disease (pAD), regional patterns of amyloid-β (Aβ) deposition are well characterized but have not been systematically compared across functional networks.ObjectiveDetermine how Aβ accumulation in functional networks ("network-amyloid burden" [NAB]) varies by age, network type (cogni...

S. Nolin, Stephanie Aghamoosa, W. Rieter et al. · 0 citations
Open access Aug 2026

Disease-specific tangle immunophenotypes distinguish hippocampal vulnerability in Alzheimer’s disease and Parkinson’s disease dementia

INTRODUCTION Tau pathology typically occurs in Alzheimeŕs disease (AD), however is also frequently present in Parkinsońs disease dementia (PDD) and Dementia with Lewy Bodies (DLB), yet its disease-specific signature is unclear. METHODS Five tau, amyloid-β, α-synuclein and neuronal markers were analysed across hippocamp...

S. Schreiner, Mónica Miranda de la Maza, G. Hammer et al. · 0 citations
Open access Jul 2026

APOE and amyloid‐tau pathology in cognitively unimpaired older adults

Apolipoprotein E (APOE) genotype shows well‐established dose‐dependent associations with higher amyloid in cognitively unimpaired (CU) adults. In contrast, associations with tau burden and cognition are less well characterized.

Carlos Albarrán Morillo, Lu-Kai Zheng, Elham Ghanbarian et al. · 0 citations
Open access Oct 2026

Amyloid, p‐tau, neurofilament light, and α‐synuclein cerebrospinal fluid biomarkers across Alzheimer's disease, dementia with Lewy bodies, and Parkinson's disease

Amyloid and tau positivity in DLB were associated with worse global cognitive outcomes, but not with motor performance, and NfL levels were elevated across diseases, and total α‐synuclein levels were associated with tau positivity.

Marianna Rizzo, C. Teunissen, H. Zetterberg et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.